CDK11B Antibody

What is CDK11B and why is it significant in cellular research?

CDK11B (Cyclin-Dependent Kinase 11B) is a protein kinase involved in critical cellular processes including cell division, RNA splicing, and DNA damage repair. Its importance stems from its regulatory functions in these essential cellular mechanisms, which when dysregulated, have been linked to various diseases including cancer . Studying CDK11B expression and function provides valuable insights into normal cellular processes and disease pathogenesis. The protein's multiple isoforms (including p58, p46, and p110) perform distinct functions, with the full-length p110 isoform primarily involved in transcription and RNA processing .

What are the key applications for CDK11B antibodies in research?

CDK11B antibodies are versatile research tools with several established applications. These include Western blotting (WB) for protein expression analysis, immunohistochemistry (IHC) for tissue localization studies, immunofluorescence (IF) for subcellular localization, immunocytochemistry (ICC) for cellular expression patterns, and enzyme-linked immunosorbent assay (ELISA) for quantitative detection . These applications allow researchers to investigate CDK11B expression levels, localization, and interactions with other proteins across different experimental models and conditions, providing comprehensive insights into its biological functions.

How do I select the appropriate CDK11B antibody for my research?

Selecting the appropriate CDK11B antibody requires careful consideration of several factors. First, determine which species you're studying, as different antibodies show varying reactivity with human, mouse, rat, and other species . Next, consider which epitope or region of the protein you wish to target (N-terminal, specific amino acid sequences, etc.) based on your research question . The application method (WB, IHC, IF, ELISA) is also crucial, as antibodies perform differently across techniques. Finally, consider the clonality (polyclonal vs. monoclonal) and conjugation status based on your experimental design and detection methods . For challenging experiments, antibodies validated against multiple applications and species offer greater flexibility.

What is the difference between CDK11A and CDK11B, and how does this affect antibody selection?

CDK11A and CDK11B are highly homologous proteins that may arise from the same gene in some species . In human research, CDK11B antibodies may cross-react with CDK11A due to sequence similarities, which can complicate interpretation of results. When selecting antibodies, examine the immunogen sequence carefully to determine if it might detect both proteins. For experiments requiring specific detection of only CDK11B, choose antibodies raised against unique regions that differ from CDK11A. In cases where distinguishing between these proteins is critical, validation experiments using recombinant proteins or knockdown approaches should be conducted to confirm specificity .

What are the optimal conditions for Western blotting with CDK11B antibodies?

For optimal Western blotting results with CDK11B antibodies, begin with careful sample preparation. Since CDK11B is expressed in both cytoplasmic and nuclear compartments, use an extraction buffer that efficiently solubilizes proteins from both locations . The calculated molecular weight of CDK11B is approximately 93kDa, but different isoforms may appear at different positions on the gel . For electrophoresis, use 8-10% SDS-PAGE gels to achieve good separation in this molecular weight range. When transferring, semi-dry transfer for 60-90 minutes or wet transfer overnight at 30V (4°C) typically yields good results. For antibody incubation, the recommended dilution ranges from 1:500 to 1:2000 depending on the specific antibody . Always include positive controls such as HeLa cell lysates or mouse brain tissue extracts, which have been validated for CDK11B expression .

How can I validate the specificity of a CDK11B antibody in my experimental system?

Validating antibody specificity is critical for ensuring reliable results. A comprehensive validation approach includes multiple strategies. First, perform knockdown experiments using siRNA or shRNA targeting CDK11B to confirm that the signal decreases proportionally to protein reduction . Second, overexpress tagged CDK11B in a suitable cell line and confirm co-localization of the antibody signal with the tag. Third, use multiple antibodies targeting different epitopes of CDK11B to confirm consistent results. Fourth, include negative controls such as isotype-matched IgG controls. For definitive validation, peptide competition assays can be performed, where pre-incubation of the antibody with the immunizing peptide should eliminate specific signals. Finally, cross-validation with orthogonal techniques such as mass spectrometry can provide additional confirmation of specificity.

What are the critical considerations for immunohistochemistry with CDK11B antibodies?

Successful immunohistochemistry with CDK11B antibodies requires attention to several critical factors. Fixation protocol significantly impacts epitope accessibility; generally, 10% neutral buffered formalin fixation for 24 hours works well, but optimization may be needed. Antigen retrieval is typically necessary - try both heat-induced epitope retrieval (in citrate buffer pH 6.0 or EDTA buffer pH 9.0) and enzymatic retrieval to determine optimal conditions. The recommended dilution range for IHC is 1:50 to 1:200 , but titration experiments should be performed. Include both positive controls (tissues known to express CDK11B) and negative controls (primary antibody omission and isotype controls). Because CDK11B localizes to both nucleus and cytoplasm , evaluate subcellular localization patterns carefully. Finally, for quantitative analysis, consider digital image analysis to objectively measure staining intensity and distribution.

How can I optimize immunofluorescence experiments with CDK11B antibodies?

Optimizing immunofluorescence with CDK11B antibodies requires careful attention to fixation, permeabilization, and blocking conditions. For adherent cell lines, 4% paraformaldehyde (10-15 minutes at room temperature) typically provides good fixation while preserving antigen recognition. Since CDK11B has nuclear localization, thorough permeabilization with 0.1-0.3% Triton X-100 is essential. Use a blocking solution containing 1-5% BSA or 5-10% normal serum from the same species as the secondary antibody. The optimal primary antibody dilution typically ranges from 1:50 to 1:200 , but always perform titration experiments. Counterstain with DAPI to visualize nuclei, which aids in confirming the expected nuclear localization of CDK11B. For dual labeling experiments, consider co-staining with markers of RNA processing bodies or cell cycle phases to investigate CDK11B's functional associations. Confocal microscopy is recommended for detailed subcellular localization studies.

What are common issues in Western blot detection of CDK11B and how can they be resolved?

Several challenges can arise when detecting CDK11B by Western blotting. One common issue is weak or absent signal, which may result from insufficient protein extraction, particularly from the nuclear fraction where CDK11B is abundant . To resolve this, use RIPA buffer supplemented with nuclear extraction reagents. Multiple bands or unexpected band sizes can occur due to CDK11B's multiple isoforms (p110, p58, p46) . Confirm which isoform your antibody should detect based on the immunogen sequence. High background may result from insufficient blocking or excessive antibody concentration; optimize blocking (try 5% non-fat milk or BSA) and dilute antibody appropriately (typically 1:500-1:2000) . If signal is completely absent despite optimization, verify sample preparation using a housekeeping protein control and consider changing to an antibody targeting a different epitope of CDK11B. For inconsistent results between experiments, standardize lysate preparation and loading, and consider using a loading control specific to the subcellular compartment of interest.

How do I interpret complex patterns of CDK11B expression in cells and tissues?

Interpreting CDK11B expression patterns requires understanding its biology and potential technical artifacts. CDK11B shows both nuclear and cytoplasmic localization , with distribution patterns that may vary depending on cell type, cell cycle phase, and physiological state. To interpret complex patterns accurately, first establish baseline expression in normal controls. For quantitative analysis, use digital image analysis software to objectively measure staining intensity. When comparing different samples, assess both intensity and subcellular distribution patterns. In tissues, evaluate expression in different cell types and correlate with morphological features. Be aware that the specific isoform detected by your antibody may influence the pattern observed. For cell cycle-dependent changes, synchronize cells and analyze CDK11B at different cycle phases. Finally, validate unusual patterns using orthogonal methods such as RNA analysis or alternative antibodies targeting different epitopes.

How can I distinguish between specific and non-specific binding when using CDK11B antibodies?

Distinguishing between specific and non-specific binding is critical for accurate data interpretation. Implement multiple control strategies including: (1) Primary antibody omission controls to identify background from secondary antibodies; (2) Isotype controls using non-specific IgG from the same species at the same concentration; (3) Pre-absorption controls where the antibody is pre-incubated with its immunizing peptide before application; (4) siRNA knockdown controls to confirm signal reduction corresponds with protein reduction ; (5) Multiple antibodies targeting different epitopes to confirm consistent patterns. For Western blots, specific binding should appear at the expected molecular weight (~93kDa for full-length CDK11B) , while non-specific binding often appears as multiple unexpected bands. In immunostaining, specific signals should show the expected subcellular localization (nuclear and cytoplasmic for CDK11B) and be consistent with the protein's known biology.

What challenges might arise when studying CDK11B in different species, and how can they be addressed?

Studying CDK11B across species presents several challenges. First, sequence homology varies between species, affecting antibody cross-reactivity. While many CDK11B antibodies react with human and mouse samples , reactivity with other species may be limited. To address this, verify the sequence homology between the antibody's immunogen and the target species' CDK11B sequence. Second, isoform expression patterns may differ between species, resulting in different banding patterns or localization. For accurate cross-species comparisons, use antibodies targeting highly conserved regions. Third, regulatory mechanisms governing CDK11B expression and function may vary across species, complicating functional studies. When extending findings from one species to another, validate key observations independently in each species. Finally, for species lacking validated CDK11B antibodies, consider generating custom antibodies against conserved epitopes or using alternative approaches such as tagged expression constructs or mass spectrometry-based protein identification.

How can CDK11B antibodies be used to investigate its role in cancer biology?

CDK11B antibodies enable several sophisticated approaches to cancer research. Immunohistochemical analysis of tissue microarrays can reveal expression patterns across different cancer types and stages, correlating expression with clinical outcomes . Co-immunoprecipitation with CDK11B antibodies followed by mass spectrometry can identify novel interaction partners specific to cancer cells. Chromatin immunoprecipitation (ChIP) using CDK11B antibodies can map its genomic binding sites to understand transcriptional regulation in cancer. For functional studies, combine siRNA knockdown with CDK11B immunoblotting to validate knockdown efficiency before assessing phenotypic effects. Phospho-specific CDK11B antibodies (if available) can monitor kinase activation status in response to treatment. In patient-derived xenografts or organoids, immunofluorescence with CDK11B antibodies can track expression during tumor evolution or treatment response. This multi-faceted approach provides comprehensive insights into CDK11B's contributions to cancer initiation, progression, and treatment response.

How can I use CDK11B antibodies to study its role in RNA processing and splicing?

Investigating CDK11B's role in RNA processing requires specialized applications of antibodies. RNA immunoprecipitation (RIP) can be performed by using CDK11B antibodies to pull down protein-RNA complexes, followed by RNA sequencing to identify bound transcripts. For spatial analysis, immunofluorescence with CDK11B antibodies combined with FISH (fluorescent in situ hybridization) for specific RNAs can visualize co-localization at the single-cell level. To study dynamic associations with splicing machinery, perform co-immunoprecipitation with CDK11B antibodies followed by Western blotting for splicing factors or mass spectrometry analysis. For functional studies, combine siRNA-mediated CDK11B knockdown (verified by immunoblotting) with RNA-seq to identify splicing changes. Chromatin immunoprecipitation sequencing (ChIP-seq) using CDK11B antibodies can reveal associations with chromatin during co-transcriptional splicing. For mechanistic insight, use CDK11B antibodies in conjunction with phospho-specific antibodies against splicing factors to determine if they are CDK11B substrates.

What are the considerations for using CDK11B antibodies in high-throughput screening or drug discovery research?

Using CDK11B antibodies in high-throughput screening (HTS) requires careful optimization and validation. For cell-based screens, develop robust immunofluorescence or ELISA protocols with CDK11B antibodies that give consistent results across plates and days. Z-factor determination is essential to ensure assay quality. For target validation in drug discovery, confirm antibody specificity using genetic approaches (CRISPR knockout or RNAi ) before screening compounds. When screening for compounds that modulate CDK11B expression or localization, use multiple antibodies targeting different epitopes to confirm results. For evaluating compound effects on CDK11B-protein interactions, optimize co-immunoprecipitation protocols for higher throughput formats. If developing phosphorylation-specific assays, consider in-cell western techniques with phospho-specific antibodies (if available) or generic phospho-antibodies following CDK11B immunoprecipitation. Finally, establish clear criteria for hit selection based on statistical significance and biological relevance, with secondary validation using orthogonal techniques to minimize false positives.

What is the comparative performance of different CDK11B antibodies across various applications?

The performance of CDK11B antibodies varies significantly across applications and targets, necessitating careful selection based on experimental needs. The table below summarizes the comparative characteristics of several CDK11B antibodies based on the search results:

When selecting between these options, consider that antibodies targeting different epitopes may yield different results, particularly if studying specific isoforms or phosphorylation states. For comprehensive studies, using multiple antibodies targeting different regions can provide validation through convergent results.

How should experimental controls be designed when using CDK11B antibodies?

Rigorous experimental controls are essential when working with CDK11B antibodies. Positive controls should include samples known to express CDK11B, such as HeLa cells or mouse brain tissue . For negative controls, implement a tiered approach: (1) Technical controls: primary antibody omission, isotype-matched irrelevant antibodies, and secondary antibody-only controls; (2) Biological controls: cell lines or tissues with low/no CDK11B expression or CDK11B-knockdown samples ; (3) Specificity controls: pre-incubation of antibody with immunizing peptide to block specific binding. For quantitative studies, include a standard curve using recombinant CDK11B protein. When studying phosphorylation or activation, include appropriate treatment controls (serum starvation, cell cycle synchronization, etc.). For co-localization studies, single-channel controls are essential to rule out bleed-through. Document all controls thoroughly and include representative images or data in publications to demonstrate antibody validation.

What sample preparation techniques optimize CDK11B detection in different experimental systems?

Sample preparation significantly impacts CDK11B detection across different experimental systems. For protein extraction in Western blotting, use RIPA buffer supplemented with phosphatase and protease inhibitors, as CDK11B is subject to phosphorylation and degradation. Since CDK11B localizes to both cytoplasm and nucleus , include nuclear extraction steps (e.g., brief sonication or specific nuclear extraction buffers). For immunohistochemistry, 10% neutral buffered formalin fixation followed by paraffin embedding works well, but antigen retrieval is critical - test both heat-induced (citrate buffer pH 6.0 and EDTA buffer pH 9.0) and enzymatic methods. For immunofluorescence of cultured cells, 4% paraformaldehyde fixation with 0.1-0.3% Triton X-100 permeabilization typically provides good results. For co-immunoprecipitation studies, gentler lysis buffers (containing 0.5% NP-40 or 1% Triton X-100) better preserve protein-protein interactions. When studying splice variants or isoforms, carefully select lysis conditions that extract all relevant forms equally to avoid biased detection.

How can CDK11B antibodies be integrated with other techniques for comprehensive functional studies?

Integrating CDK11B antibody-based techniques with complementary approaches creates powerful experimental paradigms. Combine CDK11B immunoprecipitation with mass spectrometry to identify novel interaction partners or post-translational modifications. Integrate CRISPR/Cas9 genome editing to create knockout or knock-in cell lines, using CDK11B antibodies to validate editing efficiency. Pair CDK11B immunofluorescence with live-cell imaging of fluorescently tagged proteins to correlate fixed-cell observations with dynamic behaviors. Combine ChIP-seq using CDK11B antibodies with RNA-seq following CDK11B depletion to connect genomic binding with transcriptional outcomes. Use proximity ligation assays with CDK11B antibodies and antibodies against potential interaction partners to visualize protein complexes in situ. For translational research, correlate tissue microarray analysis using CDK11B antibodies with patient metadata to identify clinically relevant expression patterns. Finally, integrate CDK11B antibody-based screening with computational approaches such as network analysis to place findings in broader biological context.